EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS

Matthias Saar iD, Karim Fizazi, Neal D Shore, Matthew Smith, Jan-Erik Damber, Andrey Semenov, Maria J Ribal, Alison Birtle, Jérôme Rigaud, Christopher J D Wallis, Marc-Oliver Grimm, Susan Halabi und 7 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.71343 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Matthias Saar und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Pediatric Urology, University Medical Center RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Quality of Life, Prostatectomy, Prostatic Neoplasms, Castration-Resistant, Pyrazoles. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer AG, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Darolutamide plus androgen‐deprivation therapy (ADT) improved metastasis‐free survival (MFS) by 2 years and reduced the risk of death by 31% in nonmetastatic castration‐resistant prostate cancer (nmCRPC) in ARAMIS. Prior local therapy may influence the efficacy of subsequent systemic therapy. This post hoc analysis of ARAMIS evaluated the effect of prior local therapy on the efficacy and health‐related quality of life (HRQoL) of darolutamide.

Methods

Patients with nmCRPC were randomized to darolutamide ( n = 955) or placebo ( n = 554) while continuing ADT. MFS, overall survival (OS), time to prostate‐specific antigen (PSA) progression, and HRQoL deterioration‐free survival (DetFS) were estimated for patients with and without local therapy and by treatment using Kaplan–Meier methods.

Results

Darolutamide increased MFS versus placebo in patients with (HR, 0.36; 95% CI, 0.26–0.48) and without (HR, 0.46; 95% CI, 0.36–0.59) local therapy. Median OS was 48.6 months for placebo without local therapy and not reached in either the darolutamide group or placebo group with local therapy. Darolutamide 3‐year OS rates were 86.9% (95% CI, 83.0–90.8) and 79.0% (95% CI, 66.2–78.1) in patients with and without local therapy, respectively. Darolutamide showed evidence of improved OS versus placebo in patients with prior local therapy (HR, 0.80; 95% CI, 0.50–1.30) and a greater effect in those without local therapy (HR, 0.67; 95% CI, 0.50–0.90). Darolutamide delayed time to PSA progression and HRQoL deterioration regardless of local therapy.

Conclusions

Darolutamide versus placebo improved MFS, OS, time to PSA progression, and HRQoL DetFS independent of prior local therapy, consistent with the overall ARAMIS population. Trial Registration: ClinicalTrials.gov registration: NCT02200614

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeProstatectomyProstatic Neoplasms, Castration-ResistantPyrazolesHumansMaleAgedMiddle AgedProstate-Specific AntigenTreatment Outcome

Stichwörter der Autor:innen

androgen receptor inhibitordarolutamidemetastatic‐free survivalnonmetastatic, castration‐resistant prostate canceroverall survivalprostatectomyradiotherapy

Substanzen

darolutamidePyrazolesProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology and Pediatric Urology, University Medical Center RWTH Aachen, Aachen, Germany.
  • Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
  • Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.
  • University of Gothenburg, Gothenburg, Sweden.
  • Ivanovo Regional Oncology Dispensary, Ivanovo, Russia.

ORCID-Profile: Matthias Saar

Förderung

  • Bayer AG
  • Bayer

Zitieren

APA

Saar, M., Fizazi, K., Shore, N. D., Smith, M., Damber, J. E., Semenov, A., Ribal, M. J., Birtle, A., Rigaud, J., Wallis, C. J. D., Grimm, M. O., Halabi, S., Armstrong, A. J., Mohamed, A. F., Adorjan, P., Srinivasan, S., Verholen, F., Morgans, A. K., & Siemens, D. R. (2026). Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS. Cancer Medicine. https://doi.org/10.1002/cam4.71343

Vancouver

Saar M, Fizazi K, Shore ND, Smith M, Damber JE, Semenov A, et al. Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS. Cancer Medicine. 2026. doi:10.1002/cam4.71343

BibTeX
@article{Saar2026,
  author = {Saar, Matthias and Fizazi, Karim and Shore, Neal D and Smith, Matthew and Damber, Jan-Erik and Semenov, Andrey and Ribal, Maria J and Birtle, Alison and Rigaud, Jérôme and Wallis, Christopher J D and Grimm, Marc-Oliver and Halabi, Susan and Armstrong, Andrew J and Mohamed, Ateesha F and Adorjan, Patrick and Srinivasan, Shankar and Verholen, Frank and Morgans, Alicia K and Siemens, D Robert},
  title = {Effects of Prior Local Therapy by Radical Prostatectomy or Radiotherapy on the Efficacy and Quality of Life of Patients Treated With Darolutamide in ARAMIS},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71343}
}
Kostenlos starten →